Fast disperisble ibuprofen tablets

被引:132
作者
Schiermeier, S [1 ]
Schmidt, PC [1 ]
机构
[1] Univ Tubingen, Dept Pharmaceut Technol, D-72076 Tubingen, Germany
关键词
dispersible tablets; disintegration; ibuprofen; orodispersible tablet; optimization; suspension;
D O I
10.1016/S0928-0987(02)00011-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fast dispersible tablets disintegrate either rapidly in water, to form a stabilized suspension, or disperse instantaneously in the mouth to be swallowed without the aid of water. A direct compression method was used to prepare these two types of tablets containing coated ibuprofen as a high dosed model drug. The properties of the water dispersible tablet, such as porosity, hardness, disintegration time and increase in viscosity after dispersion, were investigated. The selected tablet formulation, containing 26% galactomannan and 5% crospovidone, disintegrates before the galactomannan starts to swell. These tablets disperse in water within 40 s and show a crushing strength of 95 N. To develop an orodispersible tablet, a rotatable central composite design was applied to predict the effects of the quantitative factors mannitol and crospovidone as well as compression force on the characteristics of the tablet. Special emphasis was paid to the development of a wetting test, replacing the normal disintegration method. An optimum tablet formulation, containing 34% mannitol and 13% crospovidone, provides a short wetting time of 17 s and a sufficient crushing strength of 40 N. In conclusion, fast dispersible tablets with acceptable hardness and desirable taste could be prepared within the optimum region. (C) 2002 Elsevier Science B.Y. All rights reserved.
引用
收藏
页码:295 / 305
页数:11
相关论文
共 31 条
  • [1] [Anonymous], 2001, EUR PHARM S, P1666
  • [2] Armstrong N.A., 1990, UNDERSTANDING EXPT D, P27
  • [3] Bi YX, 1996, CHEM PHARM BULL, V44, P2121
  • [4] Evaluation of rapidly disintegrating tablets prepared by a direct compression method
    Bi, YX
    Sunada, H
    Yonezawa, Y
    Danjo, K
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (05) : 571 - 581
  • [5] BOLTON S, 1984, DRUGS PHARM SCI, V25, P218
  • [6] Caramella C, 1984, INT J PHARM TECHNOL, V2, P1
  • [7] CHAKRABARTI P K, 1992, Indian Journal of Pharmaceutical Sciences, V54, P107
  • [8] CHANG RK, 2000, PHARM TECHNOL, V24, P52
  • [9] Cousin G, 1995, US Patent, Patent No. 5464632
  • [10] Dobetti L., 2000, PHARM TECHNOL EUR, V12, P32